


PHARMACEUTICAL 2023

IVERIC bio Inc. Rank 115 of 446









IVERIC bio Inc. Rank 115 of 446

The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 115% points. The greatest weakness of IVERIC bio Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 141% points above the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 662,826 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 35,587 |
| Liabilities, Non-Current | 96,579 |
| Other Assets | 3,051 |
| Other Compr. Net Income | -139 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 4,695 |
| Other Revenues | 0 |
| Property and Equipment | 946 |
| Research and Development | 117,012 |
| Selling, General and Administrative Expense | 72,894 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 666,823 |
| Liabilities | 132,166 |
| Expenses | 189,906 |
| Revenues | 0 |
| Stockholders Equity | 534,657 |
| Net Income | -185,211 |
| Comprehensive Net Income | -185,280 |
| Economic Capital Ratio | 184% |

